Literature DB >> 26933083

Selective Stimulation of Cardiac Lymphangiogenesis Reduces Myocardial Edema and Fibrosis Leading to Improved Cardiac Function Following Myocardial Infarction.

Orianne Henri1, Chris Pouehe1, Mahmoud Houssari1, Ludovic Galas1, Lionel Nicol1, Florence Edwards-Lévy1, Jean-Paul Henry1, Anais Dumesnil1, Inès Boukhalfa1, Sébastien Banquet1, Damien Schapman1, Christian Thuillez1, Vincent Richard1, Paul Mulder1, Ebba Brakenhielm1.   

Abstract

BACKGROUND: The lymphatic system regulates interstitial tissue fluid balance, and lymphatic malfunction causes edema. The heart has an extensive lymphatic network displaying a dynamic range of lymph flow in physiology. Myocardial edema occurs in many cardiovascular diseases, eg, myocardial infarction (MI) and chronic heart failure, suggesting that cardiac lymphatic transport may be insufficient in pathology. Here, we investigate in rats the impact of MI and subsequent chronic heart failure on the cardiac lymphatic network. Further, we evaluate for the first time the functional effects of selective therapeutic stimulation of cardiac lymphangiogenesis post-MI. METHODS AND
RESULTS: We investigated cardiac lymphatic structure and function in rats with MI induced by either temporary occlusion (n=160) or permanent ligation (n=100) of the left coronary artery. Although MI induced robust, intramyocardial capillary lymphangiogenesis, adverse remodeling of epicardial precollector and collector lymphatics occurred, leading to reduced cardiac lymphatic transport capacity. Consequently, myocardial edema persisted for several months post-MI, extending from the infarct to noninfarcted myocardium. Intramyocardial-targeted delivery of the vascular endothelial growth factor receptor 3-selective designer protein VEGF-CC152S, using albumin-alginate microparticles, accelerated cardiac lymphangiogenesis in a dose-dependent manner and limited precollector remodeling post-MI. As a result, myocardial fluid balance was improved, and cardiac inflammation, fibrosis, and dysfunction were attenuated.
CONCLUSIONS: We show that, despite the endogenous cardiac lymphangiogenic response post-MI, the remodeling and dysfunction of collecting ducts contribute to the development of chronic myocardial edema and inflammation-aggravating cardiac fibrosis and dysfunction. Moreover, our data reveal that therapeutic lymphangiogenesis may be a promising new approach for the treatment of cardiovascular diseases.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  edema; edema, cardiac; fibrosis; heart failure; lymphatic vessels; therapeutics; vascular endothelial growth factor C; ventricular remodeling

Mesh:

Substances:

Year:  2016        PMID: 26933083     DOI: 10.1161/CIRCULATIONAHA.115.020143

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  107 in total

1.  Apelin modulates pathological remodeling of lymphatic endothelium after myocardial infarction.

Authors:  Florence Tatin; Edith Renaud-Gabardos; Anne-Claire Godet; Fransky Hantelys; Francoise Pujol; Florent Morfoisse; Denis Calise; Fanny Viars; Philippe Valet; Bernard Masri; Anne-Catherine Prats; Barbara Garmy-Susini
Journal:  JCI Insight       Date:  2017-06-15

Review 2.  Immune cell trafficking, lymphatics and hypertension.

Authors:  Dakshnapriya Balasubbramanian; Catalina A Lopez Gelston; Joseph M Rutkowski; Brett M Mitchell
Journal:  Br J Pharmacol       Date:  2018-06-25       Impact factor: 8.739

3.  Rasip1 controls lymphatic vessel lumen maintenance by regulating endothelial cell junctions.

Authors:  Xiaolei Liu; Xiaowu Gu; Wanshu Ma; Michael Oxendine; Hyea Jin Gil; George E Davis; Ondine Cleaver; Guillermo Oliver
Journal:  Development       Date:  2018-08-20       Impact factor: 6.868

Review 4.  Angiogenic gene therapy in cardiovascular diseases: dream or vision?

Authors:  Seppo Ylä-Herttuala; Charles Bridges; Michael G Katz; Petra Korpisalo
Journal:  Eur Heart J       Date:  2017-05-07       Impact factor: 29.983

Review 5.  Lymphangiogenesis: fuel, smoke, or extinguisher of inflammation's fire?

Authors:  Gabriella R Abouelkheir; Bradley D Upchurch; Joseph M Rutkowski
Journal:  Exp Biol Med (Maywood)       Date:  2017-03-07

6.  Therapeutic lymphangiogenesis after myocardial infarction: vascular endothelial growth factor-C paves the way.

Authors:  Polina Goichberg
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

7.  Adrenomedullin Induces Cardiac Lymphangiogenesis After Myocardial Infarction and Regulates Cardiac Edema Via Connexin 43.

Authors:  Claire E Trincot; Wenjing Xu; Hua Zhang; Molly R Kulikauskas; Thomas G Caranasos; Brian C Jensen; Amélie Sabine; Tatiana V Petrova; Kathleen M Caron
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

8.  A Second Heart Field-Derived Vasculogenic Niche Contributes to Cardiac Lymphatics.

Authors:  Ghislaine Lioux; Xiaolei Liu; Susana Temiño; Michael Oxendine; Estefanía Ayala; Sagrario Ortega; Robert G Kelly; Guillermo Oliver; Miguel Torres
Journal:  Dev Cell       Date:  2020-01-09       Impact factor: 12.270

Review 9.  Acute and chronic phagocyte determinants of cardiac allograft vasculopathy.

Authors:  Kristofor Glinton; Matthew DeBerge; Xin-Yi Yeap; Jenny Zhang; Joseph Forbess; Xunrong Luo; Edward B Thorp
Journal:  Semin Immunopathol       Date:  2018-08-23       Impact factor: 9.623

10.  Lymphangiogenic therapy prevents cardiac dysfunction by ameliorating inflammation and hypertension.

Authors:  LouJin Song; Xian Chen; Terri A Swanson; Brianna LaViolette; Jincheng Pang; Teresa Cunio; Michael W Nagle; Shoh Asano; Katherine Hales; Arun Shipstone; Hanna Sobon; Sabra D Al-Harthy; Youngwook Ahn; Steven Kreuser; Andrew Robertson; Casey Ritenour; Frank Voigt; Magalie Boucher; Furong Sun; William C Sessa; Rachel J Roth Flach
Journal:  Elife       Date:  2020-11-17       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.